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Examining the role of insulin in the regulation of cardiovascular health 
 
 
SUMMARY  
 
A substantial body of evidence has reported insulin has direct actions on the cardiovascular 
system independent of its systemic effects on plasma glucose or lipids. In particular, insulin 
regulates endothelial synthesis of the vasoactive mediators nitric oxide and endothelin-1, yet the 
importance of this in the maintenance of cardiovascular health remains poorly understood.  
Recent studies using animals with targeted downregulation of insulin signaling in vascular 
tissues are improving our understanding of the role of insulin in vascular health. This article 
focuses on the direct actions of insulin in cardiovascular tissues, with particular emphasis on the 
molecular mechanisms of insulin action on endothelial function. The potential contribution of 
impaired vascular insulin action to the cardiovascular complications of diabetes will also be 
discussed. 
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 Insulin is a key hormonal regulator of glucose homeostasis, acting to store excess plasma 
glucose as glycogen in muscle and liver or triglyceride in adipose tissue. To achieve this, insulin 
stimulates glucose uptake in striated muscle and adipocytes, glycogenesis in liver and muscle, 
glucose phosphorylation in liver and suppresses hepatic gluconeogenesis. Furthermore, insulin 
has marked effects on lipid metabolism, including the stimulation of fatty acid and triglyceride 
synthesis and suppression of lipolysis [1].  
 Diabetes mellitus is characterized by insulin insufficiency due to autoimmune destruction 
of insulin-secreting β-cells or systemic insulin resistance. Obesity is a central factor in the 
development of insulin resistance, when the capacity of adipocytes to store triglyceride is 
exceeded, leading to inappropriate lipid storage in other tissues, including skeletal muscle and 
the liver [1,2]. Metabolites of this ectopic lipid and increased circulating fatty acid concentrations 
impair insulin sensitivity in target tissues. In parallel, infiltration of adipose tissue with 
macrophages and other leukocytes occurs, promoting a chronic, subclinical pro-inflammatory 
environment in which pro-inflammatory cytokines also impair insulin sensitivity [2]. To maintain 
glycemia, insulin resistance leads to compensatory hyperinsulinemia prior to the development of 
frank diabetes. As a consequence, patients with diabetes exhibit hyperglycemia and 
dysregulated lipid metabolism and storage.  
 Insulin resistance and diabetes are associated with a markedly increased risk of 
developing macrovascular and microvascular cardiovascular disease. Indeed, cardiovascular 
diseases are the principal cause of morbidity and mortality in patients with diabetes [101]. The 
mechanisms that underlie the predisposition of people with diabetes to cardiovascular disease 
are, however, incompletely understood although multiple lines of evidence indicate that 
endothelial dysfunction, characterized by reduced nitric oxide (NO) bioavailability, is a key early 
step in the development of the cardiovascular complications of diabetes [3]. The abnormal 
glucose and lipid metabolism observed in patients with insulin resistance/diabetes in addition to 
increased circulating proinflammatory cytokines promote cardiovascular disease, yet substantial 
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evidence demonstrates that insulin directly influences cardiovascular biology independent of its 
metabolic actions. Furthermore, the direct cardiovascular actions of insulin may be impaired in 
insulin resistance and diabetes, such that vascular insulin resistance co-exists with systemic 
insulin resistance. 
 This article describes the direct effects of insulin on the cardiovascular system, with a 
particular emphasis on the current understanding of insulin signaling and actions in blood 
vessels in normal physiology and insulin resistance.  
 
Insulin signaling  
 Insulin binding to the dimeric insulin receptor (IR) tyrosine kinase stimulates 
autophosphorylation of the intracellular domains and the resultant phosphotyrosine motifs serve 
as docking sites for adapter proteins including the insulin receptor substrate (IRS) proteins, Shc 
(Src-homology and collagen-like) proteins and APS (adaptor protein with pleckstrin homology 
and Src homology 2 domains) [4,5,6].  This simple ligand-receptor binding model is complicated 
by the closely-related insulin-like growth factor-1 (IGF-1) receptors (IGFRs), which can form 
heterodimers with the IR, leading to the possible expression of IR homodimers, IGFR 
homodimers and IR-IGFR heterodimers on the cell surface, all of which may respond to insulin 
or IGF-1 with different specificity [6]. 
 Upon binding to phosphotyrosine residues on the activated IR, IRSs are phosphorylated 
by the IR on tyrosine residues, generating docking sites for the recruitment of the lipid kinase 
phosphatidylinositol 3’-kinase (PI3K), which generates phosphatidylinositol-3,4,5-trisphosphate 
(PIP3). The newly-synthesized PIP3 recruits the serine/threonine protein kinase Akt (also known 
as protein kinase B) to the plasma membrane, and Akt is subsequently phosphorylated and 
activated by phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin 
complex 2 (mTORC2) (Figure 1). The IR-IRS-PI3K-Akt pathway is the principal signaling 
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pathway by which insulin exerts the majority of its metabolic effects including stimulation of 
glucose transport and inhibition of gluconeogenesis [4,5]. 
 Insulin stimulation of IR stimulates binding of growth factor receptor-bound protein 2 
(Grb2) to Shc, which subsequently activates the guanine nucleotide exchange factor Son of 
Sevenless (SOS). Activated SOS stimulates the small G-protein Ras, which initiates the Raf-
MEK-ERK1/2 protein kinase cascade (Figure 1), associated with the mitogenic, growth-
promoting actions of insulin [4,7].  
 APS recruitment to phosphotyrosine motifs on the activated insulin receptor initiates 
recruitment of a complex containing c-Cbl and c-Cbl-associated protein (CAP). Tyrosine 
phosphorylation of c-Cbl by the insulin receptor causes the recruitment of an adaptor protein 
(CRK) and the guanine nucleotide exchange factor C3G to the plasma membrane. C3G 
subsequently activates the small GTPase TC10, involved in the modulation of insulin-regulated 
membrane trafficking [5].  
 
Vascular effects of insulin 
 The best characterized action of insulin in blood vessels is to stimulate vasodilation. Key 
early studies demonstrated increased leg [8] or forearm [9] blood flow in response to high 
physiological concentrations of insulin in healthy volunteers under euglycemic conditions, 
showing an independence from effects on glucose metabolism. Furthermore, the increase in 
blood flow was attenuated by an inhibitor of endothelial NO synthase (eNOS), suggesting 
insulin-stimulated vasodilation was NO-dependent [8,9]. In healthy individuals, acute infusions 
with insulin has little effect on systemic blood pressure, suggesting that increased insulin may 
increase blood flow to limb skeletal muscle in a tissue-specific manner. Increased limb blood 
flow is likely to represent the coordinated action of insulin to rapidly stimulate capillary 
recruitment in muscle via dilation of small arterioles and a slower vasodilation of larger vessels 
[7, 10]. Indeed, increased capillary recruitment is sensitive to eNOS inhibition and was observed 
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to occur within 5 minutes in rats infused with insulin, before any changes in blood flow [10]. The 
increased muscle blood flow in response to insulin subsequently leads to increased supply of 
nutrients to muscle, permitting further insulin-stimulated glucose uptake and glycogenesis 
[7,10]. Insulin has been demonstrated to have specific effects on endothelial cells, vascular 
smooth muscle and leukocytes associated with blood vessels and the cell-specific effects of 
insulin with respect to blood vessels are examined in greater depth later in this review. 
 
Cardiac actions of insulin 
 The best-characterized role of insulin in the heart is to regulate substrate utilization. As in 
skeletal muscle, insulin stimulates GLUT4-mediated glucose uptake in the heart via the PI3K-
Akt and CAP-Cbl pathways and also stimulates glucose oxidation [5,11]. Insulin also reduces 
fatty acid oxidation and utilization, despite increasing fatty acid uptake, allowing a switch from 
fatty acid to glucose oxidation upon insulin stimulation. This metabolic flexibility for ATP 
production in the heart is important to permit it to respond to the fluctuations in energy substrate 
supply that occur during intense exercise and the switch between fed and fasted states [1,11]. 
The key metabolic role of insulin in the heart has been supported by studies demonstrating 
impaired mitochondrial function and decreased flux through the TCA cycle with increased 
oxidative stress in hearts of mice with a cardiomyocyte-specific deletion of the IR [12].  
 Insulin has been reported to increase myocardial microvascular blood flow in healthy men 
[13], suggesting a similar effect to that seen in peripheral blood vessels and also has a positive 
inotropic effects in the human atrial myocardium that are sensitive to PI3K inhibitors [14]. 
Furthermore, insulin stimulation of the PI3K-Akt pathway has been reported to regulate 
numerous other cardiac processes, including hypertrophy, apoptosis and autophagy, as 
reviewed elsewhere [11,15]. Insulin infusion is used in the clinical setting to improve outcomes 
in acute coronary patients, yet the mode of action and efficacy of this is still uncertain [15]. 
 
Effects of insulin on platelets and erythrocytes 
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 Release of ATP from erythrocytes has been proposed to regulate blood flow distribution, 
particularly that of the cerebral and skeletal muscle microcirculation, due to activation of 
vascular endothelial cell purinergic receptors which subsequently stimulate NO production [16]. 
Incubation of erythrocytes from healthy volunteers with insulin ex vivo has been demonstrated 
to have no effect on basal ATP synthesis but rapidly attenuated ATP release stimulated by 
reduced oxygen tension, impairing their ability to dilate rodent arterioles [17]. This study 
therefore indicates that insulin may have a detrimental effect on erythrocyte-mediated regulation 
of blood flow in the microcirculation, yet the effect of insulin on erythrocyte function in vivo is 
poorly characterized and requires more research. 
 In contrast, insulin has been reported to stimulate ATP and adenosine release from 
platelets from healthy individuals ex vivo in a manner sensitive to inhibitors of NO synthesis 
[18]. Furthermore, stimulation of NO synthesis by insulin inhibits platelet aggregation and insulin 
infusion improved platelet responses to NO donors in volunteers with diabetes and acute 
coronary syndromes [19]. Platelet-derived adenosine/ATP might therefore contribute to insulin-
stimulated vasodilation and blood flow, whereas insulin-stimulated NO release may also reduce 
platelet aggregation. 
 
The effect of insulin on the endothelium 
As described above, insulin stimulates vasodilatation in a manner sensitive to inhibitors 
of NO synthesis. In addition to this well-described stimulation of NO synthesis by insulin, insulin 
also stimulates synthesis of the vasoconstrictor, endothelin-1 (ET-1), which can dominate under 
certain circumstances [20].  The molecular mechanisms by which insulin stimulates NO and ET-
1 synthesis are discussed further below. 
Insulin stimulation of endothelial NO synthesis      
 NO is synthesized from L-arginine, NADPH and O2, by eNOS, with L-citrulline and 
NADP+ formed as co-products.  The activity of eNOS is regulated by multiple mechanisms, 
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including allosteric activation, post-translational modification and subcellular localisation [21].  
Insulin-stimulates NO synthesis in cultured human endothelial cells and much research has 
characterized the mechanism by which this occurs. Insulin-stimulated NO synthesis in cultured 
endothelial cells is independent of Ca2+ concentration but dependent on IRS1-PI3K-PDK1-Akt 
pathway activation [1,3,7]. IGF-1 has been reported to be a markedly less effective stimulus for 
NO synthesis - indeed, recent elegant studies using mice with an endothelial-specific 
knockdown of IGFR or overexpression of IGFR have reported that the IGFR is a negative 
regulator of insulin-stimulated NO synthesis, perhaps due to formation of IR-IGFR heterodimers 
that are less sensitive to insulin than IR homodimers [22,23].  eNOS is subject to reversible 
phosphorylation at several sites [24], and Akt-mediated phosphorylation of eNOS at Ser1177, 
which reduces the requirement for Ca2+ and permits NO synthesis in the absence of increased 
cellular Ca2+ is required for insulin-stimulated NO synthesis in cultured endothelial cells (Figure 
2) [7,24]. Furthermore, Akt-mediated phosphorylation of eNOS Ser615 synergizes with Ser1177 
phosphorylation, contributing to insulin-stimulated NO synthesis [25]. However, insulin-
stimulated NO synthesis has been reported to be inhibited in the absence of altered insulin-
stimulated eNOS phosphorylation, indicating that insulin stimulates NO synthesis via both 
eNOS phosphorylation-dependent and phosphorylation-independent mechanisms [25,26]. 
Dimerisation of eNOS is required for activity and other proteins have been reported to 
interact with and regulate eNOS, including caveolin-1 and Hsp90 [27]. The association with 
caveolin-1 inhibits eNOS activity [28], whereas association with Hsp90 has been reported to 
promote eNOS activity [27]. Insulin has been reported to promote Hsp90-eNOS association in 
bovine endothelial cells, and the disruption of Hsp90-eNOS binding inhibited insulin-stimulated 
eNOS activation [7,29]. Furthermore, stimulation of human endothelial cells with insulin has 
been reported to increase transport of the eNOS substrate L-arginine in an Akt-dependent 
manner [26]. In agreement with a role for L-arginine transport in insulin-stimulated NO 
synthesis, inhibition of transport with lysine has been reported to inhibit insulin-stimulated 
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umbilical vein relaxation [30]. Asymmetric dimethylarginine (ADMA) is a naturally occurring, 
competitive inhibitor of eNOS and elevated ADMA concentrations have been reported in 
subjects with diabetes [31]. Whether insulin regulates ADMA concentrations or ADMA 
influences insulin sensitivity in the endothelium has not been characterized. 
Reactive oxygen species (ROS), such as superoxide react with NO to form 
peroxynitrites, thereby directly reducing NO bioavailability (Figure 2)[32]. Furthermore, 
superoxide-mediated oxidation of the eNOS cofactor tetrahydrobiopterin (BH4) reduces the 
activity of eNOS, which, in turn, leads to uncoupling of eNOS, resulting in further superoxide 
synthesis [32]. Insulin has been reported to inhibit myocardial peroxynitrite formation after 
ischemia/reperfusion [33] and transgenic mice with endothelium-targeted overexpression of a 
dominant-negative mutant IR exhibited increased endothelial superoxide generation [34], yet 
little is known concerning the action of insulin on ROS synthesis in endothelial cells under basal 
conditions.  Insulin has been reported to increase cellular concentrations of BH4 and mRNA 
expression of guanosine triphosphate cyclohydrolase-1, the rate-limiting enzyme for the 
synthesis of BH4, in cultured mouse brain microvascular endothelial cells [35]. Any or all of 
these phosphorylation-independent mechanisms of insulin may therefore contribute to insulin-
stimulated NO production. 
Insulin has also been demonstrated to increase the expression of eNOS at the mRNA 
and protein level in cultured endothelial cells [7, 36], supported by the reduced eNOS 
expression observed in endothelial cells from mice with an endothelial-specific deletion of the IR 
[37] Furthermore, insulin has been demonstrated recently to increase the expression of 
argininosuccinate synthase, a key enzyme in the recycling of eNOS-derived citrulline to arginine 
[36].  These data suggest that insulin may not only increase eNOS expression but co-ordinate 
this with increased substrate supply by increasing recycling of citrulline to arginine. 
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Some reports have reported that insulin may also engage mechanisms to terminate or 
limit eNOS activation.  Post-translational modification of eNOS by myristoylation and 
palmitoylation permits dynamic association with specific subcellular compartments including the 
Golgi complex and caveolae [27,28]. Insulin rapidly increases eNOS palmitoylation, which is 
required for the traffic of eNOS and caveolin-1 from a perinuclear Golgi compartment to the 
plasma membrane [28]. Inhibition of eNOS palmitoylation also increases insulin-stimulated NO 
synthesis, indicating that insulin-stimulated trafficking of eNOS to caveolae may act to terminate 
insulin-stimulated NO synthesis [28].  Insulin has also been reported to attenuate the activity of 
eNOS via proline-rich tyrosine kinase 2-stimulated phosphorylation of eNOS at Tyr657 in mouse 
lung endothelial cells, which the authors argue may be a mechanism to limit excessive NO 
production [38]. 
Insulin regulation of ET-1 synthesis 
 Active ET-1 is synthesized by ET converting enzymes and stored in Weibel-Palade 
bodies within endothelial cells. Upon stimulation, these storage granules traffic to the plasma 
membrane to release ET-1 by exocytosis. ET-1 subsequently has autocrine or paracrine effects 
mediated by ET receptors on endothelial cells and vascular smooth muscle cells (VSMCs) [39]. 
Insulin-stimulated secretion of ET-1 is PI3K-independent but ERK1/2-dependent in endothelial 
cells, yet the precise signaling mechanisms that underlie insulin-stimulated ET-1 secretion 
remain uncertain (Figure 2)[3,7,39,40]. Control of vascular tone by insulin therefore appears to 
be regulated by the balance of NO and ET-1 secretion in response to insulin, as vasodilator 
actions of insulin are enhanced by ET-1 receptor blockade in humans and animals [3,7].  
Furthermore, it is clear that NO regulates ET-1 synthesis and vice versa [7,41].  
Other endothelial effects of insulin 
 In addition to relaxation of underlying smooth muscle, endothelial PI3K activation and NO 
synthesis promotes endothelial cell proliferation and migration and suppresses leukocyte 
adhesion to endothelial cells (Figure 2) [7,21,42]. This latter effect is mediated, at least in part, 
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by reduced chemokine and adhesion molecule expression due to attenuated proinflammatory 
signaling via the transcription factor nuclear factor κB (NFκB) [43], although the molecular 
mechanism(s) by which endothelial NO suppresses NFκB remain poorly characterized. Cultured 
human endothelial cells stimulated with insulin in the absence of proinflammatory stimuli 
exhibited inhibited expression of intercellular adhesion molecule-1 (ICAM-1) in a NO-dependent 
manner, inhibited NFκB activity and reduced expression of the proinflammatory chemokine, 
monocyte chemoattractant protein-1 (MCP-1) [7,44]. The anti-atherogenic actions of insulin will 
be discussed in greater detail later in this review.  
 Finally, it has been suggested that insulin action is limited by the rate of insulin entry into 
skeletal muscle. Insulin has been reported to stimulate its own transport across the endothelium 
to underlying skeletal muscle by an IR-mediated pathway [45]. As a consequence, stimulation of 
transendothelial insulin transport may therefore contribute to insulin-stimulated glucose uptake 
in muscle [45,46].  
 
Effects of insulin in vascular smooth muscle 
 In the intact vessel, insulin-stimulated synthesis of NO or ET-1 from endothelial cells elicits 
relaxation or constriction of underlying smooth muscle (Figure 2).  NO binds to soluble 
guanylate cyclase in VSMCs, leading to increased cGMP production and activation of cGMP-
dependent protein kinase (PKG), ultimately stimulating vasorelaxation [41]. On the other hand, 
ET-1 binds to ET receptors on the VSMC surface, engaging multiple signaling pathways that 
stimulate contraction [41].  ET-1 also stimulates VSMC proliferation and migration, whereas NO 
attenuates VSMC proliferation [41]. Insulin may therefore regulate VSMC proliferation via the 
endothelium by the balance of insulin-stimulated NO and ET-1 synthesis (Figure 2).   
 In addition to these effects mediated by insulin’s endothelial actions, insulin has direct 
effects on VSMCs, stimulating relaxation, attenuating contractility and reducing Ca2+ influx [47]. 
VSMCs have been reported to express the IR, eNOS and inducible NOS (iNOS). Indeed, insulin 
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stimulation of isolated VSMCs increases NO synthesis by eNOS and iNOS in a PI3K-dependent 
manner, leading to relaxation via activation of PKG [47,48]. Insulin inhibits activation of the 
small GTPase, RhoA in a NO/cGMP-dependent manner, leading to increased myosin light 
chain phosphatase (MLCP) activity [47,49]. These effects, along with inhibition of Ca2+ influx 
and increased Ca2+ efflux are likely to underlie the direct effects of insulin on VSMC relaxation 
and contractility [47].  Finally, insulin has been reported to stimulate VSMC proliferation in an 
ERK1/2-dependent manner [50], yet VSMCs from mice lacking the IR demonstrated increased 
proliferation and migration rates, although this was associated with increased ERK1/2 signaling 
[51]. In summary, it can be seen that insulin may influence VSMC tone and proliferation by both 
direct and endothelium (NO and ET-1)-mediated effects.   
 
Regulation of vascular leukocytes by insulin 
 Despite the importance of macrophages resident in the blood vessel wall and circulating 
monocytes in the development of vascular disease, very little is known of the role of insulin in 
vascular leukocytes. Insulin stimulates the IR/IRS2/PI3K/Akt signaling cascade in macrophages 
[52], and insulin has recently been reported to inhibit the mRNA expression of the 
proinflammatory chemokine MCP-1 in mouse peritoneal macrophages, an effect that was 
ablated in macrophages lacking IRS2 [53].  The same study reported increased macrophage 
accumulation in the vascular wall of mice transplanted with IRS2-/- bone marrow, indicating 
physiological concentrations of insulin are sufficient to suppress proatherogenic macrophage 
accumulation in the absence of proinflammatory stimuli [53]. The functional consequences of 
insulin stimulation in vascular leukocytes in the healthy blood vessel are poorly characterized 
and require further research. 
 
Insulin and perivascular adipose 
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 It has recently become apparent that the thin layer of adventitia-associated perivascular 
adipose tissue (PVAT) found in small arteries and arterioles signals to and influences blood 
vessel biology [54].  PVAT responds to insulin in much the same way as other adipose tissue 
and enlargement of PVAT is observed in obesity and type 2 diabetes [54,55]. PVAT synthesizes 
a number of cytokines and chemokines, including proinflammatory tumor necrosis factor-α 
(TNFα), interleukin-6 (IL6) and MCP-1 as well as anti-inflammatory adiponectin.  As PVAT 
expands, increased free fatty acid synthesis, due to reduced anti-lipolytic effects of insulin and 
increased infiltration of PVAT with macrophages leads to increased synthesis of pro-
inflammatory cytokines and reduced synthesis of adiponectin [54]. PVAT may therefore form an 
important site of regulation of vascular function that is altered in obesity or type 2 diabetes.  
 
Attenuation of atherogenesis by insulin 
 Atherosclerosis is regarded to be a chronic inflammatory disease, the early stages of 
which involve accumulation of low-density lipoprotein (LDL) in the subendothelial space, 
increased ROS in the vessel wall and increased chemokine synthesis and adhesion molecule 
expression in endothelial cells.  Subsequently, leukocytes adhere to and migrate across the 
endothelium, forming foam cells which further increase proinflammatory signaling, migration and 
proliferation of VSMCs and synthesis of connective tissue leading to the formation of a mature 
atherosclerotic plaque.  Ultimately plaque rupture or erosion results in thrombosis and the 
occlusion of arteries [4,7]. 
 NO has anti-atherogenic actions, attenuating monocyte adhesion and VSMC proliferation, 
key early events in the development of atherosclerotic plaques. Therefore, if insulin does indeed 
stimulate biologically-relevant concentrations of NO, insulin should act to attenuate 
atherosclerosis.  In support of this, insulin, in the absence of proinflammatory stimuli, inhibited 
expression of ICAM-1 in a NO-dependent manner, inhibited activity of the key proinflammatory 
transcription factor NFκB and reduced expression of MCP-1 in human endothelial cells [7,44]. 
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 Administration of insulin for 3 days has been reported to decrease intimal area and 
increased re-endothelialization after balloon catheter injury in rat arteries, without altering 
plasma glucose concentrations significantly [56]. These studies support an anti-atherogenic 
action of insulin, yet care should be taken when assessing studies with systemic, prolonged 
treatment with insulin which may mimic hyperinsulinemia, with potential detrimental effects on 
vascular health. 
 Recent studies using mice in which vascular insulin signaling have been ablated or 
downregulated have been particularly enlightening with respect to the effect of insulin on 
atherogenesis. Atherosclerosis-prone mice transplanted with bone marrow from animals lacking 
the IR developed larger more complex atherosclerotic lesions with greater necrotic cores than 
animals transplanted with wild type bone marrow [57]. Furthermore, the macrophages lacking 
the IR showed increased apoptosis upon cholesterol loading and increased expression of 
scavenger receptor A [57], indicating loss of insulin signaling increases uptake of modified 
atherogenic LDL by macrophages and increases the severity of lesions which are more likely to 
cause acute coronary artery disease. In contrast to the study of Han and colleagues, deletion of 
insulin receptors in myeloid lineage cells (macrophages and neutrophils) decreased the size of 
lesions in atherosclerosis-prone mice [58].  The reasons for the observed differences may be 
the different cell types affected or the different diets and genetic backgrounds of the mice used. 
 In atherosclerosis-prone mice with targeted deletion of insulin receptors in the vascular 
endothelium, atherosclerotic lesion size was markedly increased, with increased expression of 
vascular cell adhesion molecule-1 (VCAM-1) and mononuclear adhesion assessed in vivo [59]. 
Importantly, insulin sensitivity, glucose tolerance, plasma lipids and blood pressure were 
unaffected compared to control animals, demonstrating that loss of insulin signaling in the 
vascular endothelium exacerbates atherosclerosis [59].   Taken together, these data support the 
hypothesis that insulin does indeed act to suppress atherogenesis and particularly reduces the 
severity of lesions.  
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Potential role of C-peptide on cardiovascular health 
 Proinsulin is cleaved in pancreatic β-cells to form insulin and C-peptide, which are 
subsequently secreted in equimolar concentrations. Although C-peptide was initially considered 
to have no biological function, a substantial number of reports now indicate that C-peptide has 
actions on the cardiovascular system. Indeed, C-peptide has been proposed to have beneficial 
effects, such as the stimulation of endothelial NO as well as detrimental, pro-inflammatory 
effects on the cardiovascular system, although these effects remain controversial [60]. It 
remains feasible, however, that direct actions of C-peptide may occur alongside insulin, 
although further research, particularly the identification of the as yet uncharacterized receptor 
for C-peptide, is required. 
 
Effect of hyperinsulinemia on vascular function 
  In cultured vascular cells, the term hyperinsulinemia has been used to describe culture in 
elevated insulin concentrations for time scales ranging from hours to weeks, whereas in vivo 
hyperinsulinemia can manifest for far longer.  Despite this, prolonged stimulation of cultured 
endothelial cells with insulin has been reported to suppress PI3K/Akt/eNOS signaling, increase 
expression of ICAM-1 and VCAM-1 expression in an ERK1/2 or p38MAPK-dependent manner 
and increase adhesion of promonocytic cells to cultured endothelial cells [61,62]. This may 
reflect engagement of IGF-1 receptors by pathophysiological rather than physiological 
concentrations of insulin [61].   
 Compensatory hyperinsulinemia is a common feature of insulin resistance prior to β-cell 
failure and can be observed prior to the onset of frank diabetes. Intriguingly, experimental 
hyperinsulinemia for as little as 3 days has been demonstrated to cause insulin resistance in 
muscle, indicating that hyperinsulinemia itself can also cause insulin resistance [4]. Separating 
a specific effect of hyperinsulinemia on vascular function is therefore often complicated in 
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clinical studies by insulin resistance and/or metabolic effects of the administered insulin. 
Hyperinsulinemia has long been considered an independent risk factor for cardiovascular 
disease and fasting plasma insulin concentrations have been reported to have an inverse 
relationship with flow-mediated dilation in healthy volunteers [63]. However, recent studies in 
atherosclerosis-prone mice haploinsufficient with respect to the IR have questioned this 
relationship. The haploinsufficient IR mice exhibited hyperinsulinemia without altered insulin 
sensitivity, yet atherosclerotic lesion size was unaffected [64]. Although the majority of the 
evidence suggests that unlike acute insulin stimulation, hyperinsulinemia may have direct 
effects on vascular cells that are detrimental to vascular health, the effects of hyperinsulinemia 
remain uncertain and require further study.  
 
Does vascular insulin resistance contribute to the cardiovascular complications of 
diabetes?  
 Obesity, dyslipidemia and pro-inflammatory signaling are central factors that contribute to 
the development of insulin resistance in classical insulin-sensitive tissues such as muscle, 
adipose and the liver [1,2].  At the molecular level, insulin resistance is thought to be due to 
metabolites of ectopic lipid stimulating protein kinase C (PKC) and/or proinflammatory cytokines 
and endoplasmic reticulum stress stimulating c-Jun N-terminal kinase (JNK) and inhibitor of 
NF8B kinase ²  (IKK² ). Activated PKC, JNK and IKK²  phosphorylate IRS-1 on inhibitory serine 
residues, inhibiting activating phosphorylation by the IR on tyrosine residues. As a 
consequence, the IRS/PI3K/Akt signaling pathway is specifically downregulated in insulin 
resistance [65] (Figure 3).  
 It is clear that insulin resistant individuals also exhibit insulin resistance in their 
cardiovascular tissues. Cardiac tissues from obese rodents or animals fed a high fat diet exhibit 
impaired insulin-stimulated glucose oxidation and increased fatty acid oxidation [66,67]. 
Furthermore, increased translocation (a measure of activity) of PKCα and increased inhibitory 
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IRS-1 serine phosphorylation was observed in cardiac tissue from animals fed a high fat diet 
[67]. This is likely to impair the ability of the heart to adapt to changes in substrate availability.  
 Insulin resistance has been observed in blood vessels, in which impaired insulin-
stimulated vasodilation and NO production is evident [4,7]. In cultured endothelial cells, 
impaired insulin-stimulated PI3K/Akt/NO synthesis has been reported in response to free fatty 
acids and pro-inflammatory signals including angiotensin II, TNFα and IL6 [25,68,69,70,71].  
Insulin-stimulated relaxation is impaired in rodent models of type 2 diabetes or obesity [38,72] 
and can be enhanced by PKC inhibitors [73].  
 Importantly, a selective insulin resistance has been observed in endothelial cells from 
volunteers with type 2 diabetes, whereby the insulin-stimulated PI3K/Akt pathway is impaired, 
yet insulin-stimulated ERK1/2 is unaffected or increased in the endothelium [7,74]. Given the 
different and opposing effects of these insulin signaling pathways on endothelial function, insulin 
resistance would be predicted to cause endothelial dysfunction, through reduced bioavailability 
of NO and unaffected or increased ET-1 synthesis. Although a number of studies utilizing 
mouse models with endothelium-specific downregulation or ablation of insulin signaling have 
reported reduced NO bioavailability, increased ROS, endothelial dysfunction and enhanced 
atherogenesis [22,34,59], the models in question have manipulated the activity at the level of 
the IR, such that both PI3K/Akt and ERK1/2 pathways would be expected to be impaired, unlike 
the endothelial insulin resistance observed in endothelial cells from patients with type 2 diabetes 
[74]. In addition, endothelium-specific downregulation of insulin signaling intermediates 
downstream of the IR would suffer from a lack of specificity as PI3K and Akt are common 
signaling pathway components for a broad range of stimuli. VSMCs isolated from rodent models 
of type 2 diabetes also exhibit impaired insulin-stimulated Akt activation [75,76], yet the 
relevance of VSMC insulin resistance is barely characterized with respect to vascular function. It 
remains uncertain; therefore, to what extent vascular insulin resistance alone contributes to 
macrovascular or microvascular complications of diabetes although the weight of evidence 
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certainly suggests that insulin does have clinically-relevant actions on blood vessels that act to 
suppress atherosclerosis. 
 
Direct vascular actions of antidiabetic pharmaceuticals 
 Intensive diabetes treatment with insulin was reported to substantially lower the risk of 
cardiovascular disease in people with type 1 diabetes, indicating that insulin has beneficial 
effects on the cardiovascular system [77]. Intriguingly, it has been recently reported that therapy 
with insulin glargine for 6 years had no effect on cardiovascular outcomes in volunteers with 
type 2 diabetes, impaired glucose tolerance or impaired fasting glucose, compared to standard 
treatment [78]. This implies that insulin has no beneficial cardiovascular effect in an insulin-
resistant group, although it should be noted that this study was not testing intensive insulin 
treatment, rather the use of insulin compared to standard care in a glycemia-controlled manner, 
in volunteers many of whom were using other oral hypoglycaemic agents. Indeed, a number of 
pharmacological agents in current use for the treatment of patients with type 2 diabetes have 
been reported to have direct vascular effects independent of their capacity to improve glycemia. 
 Metformin suppresses hepatic gluconeogenesis, thereby normalizing glycemia, yet 
metformin has also been reported to reduce the incidence of myocardial infarction and stroke in 
comparison with sulfonylurea or insulin causing matched improvement in glycemic control [79]. 
Furthermore, metformin therapy has been reported to decrease myocardial injury and improve 
left ventricular function and survival after ischemia and reperfusion [79]. These potential direct 
actions of metformin on vascular tissues are thought to be mediated, at least in part, by 
activation of AMP-activated protein kinase (AMPK) [79,80]. AMPK mimics insulin’s action in 
cardiovascular tissues by phosphorylation and activation of eNOS, stimulating NO synthesis in 
addition to NO-dependent and NO-independent suppression of endothelial pro-inflammatory 
signaling [81,82]. 
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 The thiazolidinedione (TZD) class of drugs improve insulin sensitivity by virtue of their 
stimulation of peroxisome proliferator-activated receptor-γ (PPARγ), which regulates the 
transcription of metabolic genes [83].  As with metformin, TZDs have been reported to rapidly 
stimulate NO synthesis via AMPK-stimulated phosphorylation of eNOS in cultured endothelial 
cells and also suppress pro-inflammatory signaling [81,83]. 
 Incretin based therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and 
dipeptydil-peptidase-4 (DPP-4) inhibitors are used in patients with type 2 diabetes to upregulate 
GLP-1 signaling leading to increased insulin secretion in response to a meal [84,85].  It is 
becoming apparent that these drugs also have direct effects on myocardial and endothelial cells 
including stimulation of NO and suppression of proinflammatory signaling [84,85].   
 As all of these antidiabetic agents may directly mimic the effects of insulin in the 
endothelium without altering insulin signaling whilst improving the metabolic consequences of 
diabetes, understanding the molecular mechanisms by which they act is of the utmost 
importance.  
 
Concluding remarks 
 In summary, insulin has direct effects on cardiomyocytes, endothelial cells, VSMCs, 
erythrocytes, leukocytes and platelets in vitro and there is substantial evidence that the effects 
of insulin on blood vessels contribute directly to the maintenance of cardiovascular health. 
Evidence from studies using animal models with tissue-specific downregulation of insulin 
signaling has been instrumental in demonstrating that insulin regulates substrate utilization in 
the heart, endothelial NO synthesis and has an anti-inflammatory, atheroprotective action in 
vivo. Some care should be taken when interpreting the data using these genetic models, 
however, as they may not accurately reflect defects in insulin signaling observed in insulin 
resistance. A host of factors including hyperglycemia, dyslipidemia, increased proinflammatory 
signaling and cellular reactive oxygen species are all associated with cardiovascular disease 
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and are observed in insulin resistance or diabetes such that examining the role of insulin in the 
regulation of cardiovascular health in man is complicated by systemic effects of the 
administered insulin. Furthermore, sustained elevated concentrations of insulin such as those 
observed in hyperinsulinemia may be detrimental to cardiovascular health, suggesting the 
duration of signal is important in the action of insulin. Further characterisation of the role of 
insulin in blood vessels, the signaling pathways engaged by insulin and their modulation by 
factors altered in diabetes may identify novel therapeutic targets to limit or prevent the vascular 
complications of diabetes.  
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FUTURE PERSPECTIVE 
 Although the actions of insulin in blood vessels and the heart have been partially 
characterized, significant questions remain that require resolution. Understanding the molecular 
mechanisms by which insulin acts in cardiovascular tissues is vital for the development of 
appropriate therapeutic targets for the normalization of vascular insulin resistance. Insulin 
infusion is used in the clinical setting to improve outcomes in acute coronary patients, yet there 
is still considerable debate as to its efficacy. To address this, a large multicentre randomized 
clinical trial would be exceedingly useful to confirm the protective effects of insulin on the 
cardiovascular system. Given the potential for differential effects of insulin depending on the 
duration of stimulation, future studies should concentrate on investigating the role of 
hyperinsulinemia on cardiovascular function. The endothelium is perhaps the best characterized 
to date of the cardiovascular tissues with respect to insulin action. In the future, it would be 
desirable to greatly improve our understanding of direct actions of insulin in vascular smooth 
muscle, leukocytes and PVAT, in which there is a particular dearth of information at present.  
Even in the endothelium, it is unclear how insulin stimulates eNOS as it is clear that 
phosphorylation is not the only mechanism by which eNOS is regulated. Future research 
examining the effect of insulin on eNOS trafficking, dimerisation and association with regulatory 
proteins is required to address this, as is research to assess the influence of ADMA in the action 
of insulin in healthy or insulin-resistant vessels. Inducible, tissue-specific downregulation of 
insulin signaling will would improve our understanding of what happens to the cardiovascular 
tissues when their insulin resistance becomes impaired in adulthood rather than being impaired 
for the entirety of development.   Furthermore, it is now clear that existing antidiabetic therapies 
have direct cardiovascular actions independent of their effects on metabolism. The thorough 
investigation of the mechanisms by which these cardiovascular actions are manifest is 
warranted to identify useful molecular targets for the design of future therapies. 
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EXECUTIVE SUMMARY 
Vascular effects of insulin 
• Insulin has direct effects on blood vessels, independent of effects on metabolism 
• Insulin stimulates vasodilation, capillary recruitment and improves nutrient delivery to 
muscle. 
Cardiac actions of insulin 
• Insulin stimulates glucose oxidation and attenuates fatty acid oxidation, such that 
appropriate insulin signaling is required to maintain flexibility during changes in energy 
substrate supply. 
Endothelial effects of insulin 
• Insulin stimulates synthesis of the vasodilator NO at least in part by Akt-mediated 
phosphorylation and activation of endothelial nitric oxide synthase.   
• Insulin stimulates synthesis of the vasoconstrictor endothelin-1 by an ERK1/2-dependent 
mechanism.  
• Insulin has anti-inflammatory actions that limit atherogenesis and stimulate endothelial 
cell proliferation. 
VSMC effects of insulin 
• Insulin regulates vascular tone and VSMC proliferation by endothelium-dependent and 
direct endothelium-independent actions. 
Anti-atherogenic actions of insulin 
• Insulin reduces atherogenesis, likely to be a consequence of reduced NO synthesis and 
NO-independent mechanisms that reduce pro-inflammatory signaling and limit leukocyte 
adhesion to blood vessels. 
• The direct effects of insulin on leukocytes are poorly characterized. 
Vascular insulin resistance 
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• Cardiovascular diseases are the leading cause of morbidity and mortality in people with 
insulin resistant type 2 diabetes 
• Obesity, dyslipidemia and pro-inflammatory signaling are central factors that contribute to 
the development of insulin resistance. These activate protein kinases that inhibit insulin 
signaling through the IRS/PI3K/Akt signaling pathway without altering ERK1/2 activation.  
• The balance of NO and endothelin-1 synthesis is important in the regulation of vascular 
tone and is altered in insulin resistance when NO synthesis is specifically impaired. 
• Hyperinsulinemia, present in insulin-resistant individuals prior to the development of 
diabetes may reduce NO bioavailability and promote atherogenesis, suggesting insulin 
has rapid beneficial effects on vascular health yet becomes detrimental upon long term 
stimulation.  
Future perspective 
• Insulin stimulation of IRS/PI3K/Akt signaling is specifically downregulated in insulin 
resistance. Substantial insights into the role of insulin in cardiovascular tissues have 
been obtained using rodents genetically manipulated to downregulate insulin signaling in 
specific tissues. It is still unclear, however, to what degree hyperinsulinemia is 
responsible for impaired cardiovascular function. Furthermore, future studies need to 
concentrate on further characterizing the role of insulin in vascular smooth muscle, 
vascular leukocytes and perivascular adipose tissue, which are currently under-
investigated.   
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ABBREVIATIONS 
Akt; protein kinase B; AMPK; AMP-activated protein kinase; APS, adaptor protein with 
pleckstrin homology and Src homology 2 domains; BH4, reduced tetrahydrobiopterin; CAP, c-
Cbl-associated protein; eNOS, endothelial NO synthase; ET-1, endothelin-1; GLP-1, glucagon-
like peptide-1; Grb2, growth factor receptor-bound protein 2; ICAM-1, intercellular adhesion 
molecule-1; IGF-1, insulin-like growth factor-1; IGFR, insulin-like growth factor receptor; IKK² , 
inhibitor of NF8B kinase ² ; IL6, interleukin-6; IR, insulin receptor; IRS, insulin receptor substrate; 
JNK, Jun N-terminal kinase; LDL, low density lipoprotein; MCP-1, monocyte chemoattractant 
protein-1; mTORC2, mammalian target of rapamycin complex 2; NFκB, nuclear factor κB; NO, 
nitric oxide; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3’-kinase; 
PIP3, phosphatidylinositol-3,4,5-trisphosphate; PKC, protein kinase C; PKG, cGMP-dependent 
protein kinase; PPARγ , proliferator-activated receptor-γ; PVAT, perivascular adipose tissue; 
ROS, reactive oxygen species; Shc, Src-homology and collagen-like protein; SOS, Son of 
Sevenless; TNFα, tumor necrosis factor-α; TZD, thiazolidinedione; VCAM-1, vascular cell 
adhesion molecule-1; VSMC, vascular smooth muscle cell. 
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Figure 1: Insulin signaling pathways 
Insulin (Ins) binding to the dimeric insulin receptor tyrosine kinase stimulates 
autophosphorylation leading to binding of the insulin receptor substrate (IRS) and Src-homology 
and collagen-like (Shc) adapter proteins. Upon binding to the activated insulin receptor, IRSs 
are phosphorylated, generating docking sites for the recruitment of phosphatidylinositol 3’-
kinase (PI3K), which generates phosphatidylinositol-3,4,5-trisphosphate (PIP3) from 
phosphatidylinositol-4,5-bisphosphate (PIP2). PIP3 recruits the serine/threonine protein kinase 
Akt to the plasma membrane, and Akt is subsequently phosphorylated and activated by 
phosphoinositide-dependent kinase 1 (PDK1) and mammalian target of rapamycin complex 2 
(mTORC2). The IRS-PI3K-Akt pathway is the principal signaling pathway by which insulin 
exerts the majority of its metabolic effects. Activation of the insulin receptor stimulates binding of 
growth factor receptor-bound protein 2 (Grb2) to Shc, which subsequently stimulates Son of 
Sevenless (SOS) to catalyse GDP-GTP exchange on the small G-protein Ras. GTP-bound 
active Ras initiates the Raf-MEK-ERK1/2 protein kinase cascade, which mediates many of the 
mitogenic actions of insulin.  
 37 
Ins
IRS
PI3K
PIP2 PIP3 Akt
Shc
Grb2
SOS
ERK
1/2
ET-1 synthesis
Vasoconstriction
VSMC proliferation
eNOS
NOONOO-
O2
.-
Angiogenesis
Capillary recruitment
Leukocyte adhesion
Atherogenesis
Figure 2
   
Figure 2: Insulin-stimulated NO and endothelin-1 synthesis 
Insulin (Ins) stimulates activation of Akt as described in Figure 1, which phosphorylates and 
activates endothelial NO synthase (eNOS). The NO synthesized stimulates vasodilation, 
angiogenesis and capillary recruitment, whilst inhibiting pro-atherogenic vascular smooth 
muscle cell (VSMC) proliferation, expression of the chemokine monocyte chemoattractant 
protein-1 (MCP-1) and vascular cell adhesion molecule-1 (VCAM-1). NO is sequestered by 
elevated concentrations of superoxide, leading to production of highly reactive peroxynitrite.  
Insulin stimulates the mitogenic protein kinases ERK1/2 through the pathway described in 
Figure 1, stimulating release of endothelin-1 (ET-1) which stimulates vasodilation and VSMC 
proliferation. Akt, protein kinase B; Grb2, growth factor receptor-bound protein 2; IRS, insulin 
receptor substrate; PI3K, phosphatidylinositol 3’-kinase; PIP2, phosphatidylinositol-4,5-
bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; Shc, Src-homology and collagen-
like; SOS, Son of Sevenless.  
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Figure 3: Molecular mechanism of selective insulin resistance 
Insulin resistance is reported to be due to metabolites of ectopic lipid, increased free fatty acid 
(FFA) concentrations and proinflammatory cytokines stimulating one or more of the 
serine/threonine protein kinases protein kinase C (PKC), c-Jun N-terminal kinase (JNK) and 
inhibitor of NF8B kinase ²  (IKK² ). Activated PKC, JNK and IKK²  phosphorylate insulin receptor 
substrate-1 (IRS-1) at inhibitory residues, inhibiting activation by insulin. As a consequence, Akt 
activation is suppressed, whereas insulin stimulation of ERK1/2 is unaffected. Akt, protein 
kinase B; Grb2, growth factor receptor-bound protein 2; PI3K, phosphatidylinositol 3’-kinase; 
PIP2, phosphatidylinositol-4,5-bisphosphate; PIP3, phosphatidylinositol-3,4,5-trisphosphate; 
Shc, Src-homology and collagen-like; SOS, Son of Sevenless.  
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